Adverse effects of pharmaceutical excipients

Adverse Drug Reaction Bulletin

Volumn , Issue 222, 2003, Pages 851-854

  Kumar, Ashir ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTIRETROVIRUS AGENT; CARBOMER; CELLACEFATE; CYCLAMATE SODIUM; EXCIPIENT; GELATIN; GLUTEN; GLYCEROL; GLYCOL; HERBACEOUS AGENT; MANNITOL; PARAFFIN; PHTHALIC ACID DERIVATIVE; PLASTIC; POLYOL; POLYVINYL ACETATE; RESIN; RITONAVIR; SACCHARIN; SHELLAC; SILICONE; SOLVENT; SORBITOL; SUCROSE; SUGAR ALCOHOL; SWEETENING AGENT; UNINDEXED DRUG; WAX; XYLITOL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ASTHMA; BRONCHOSPASM; CHEILITIS; CHEMICAL COMPOSITION; COLOR; CONTACT DERMATITIS; CONTAINER; DENTAL CARIES; DERMATITIS; DIARRHEA; DRUG CAPSULE; DRUG CLASSIFICATION; DRUG CONTAMINATION; DRUG DETERMINATION; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ECZEMA; ELECTROLYTE DISTURBANCE; ELIXIR; EOSINOPHILIA; ERYTHEMA MULTIFORME; FLATULENCE; FLAVOR; GASTROINTESTINAL SYMPTOM; HARDNESS; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERKINESIA; HYPOGLYCEMIA; INSOMNIA; LACTOSE INTOLERANCE; LIQUID; MALABSORPTION; MATERIAL COATING; MEDICINAL PLANT; MICROENCAPSULATION; MUCOSA INFLAMMATION; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OPISTHOTONUS; PALATABILITY; PANNICULITIS; PARTICLE SIZE; PHOTOSENSITIVITY; PRURITUS; RASH; REVIEW; RHINITIS; SHOCK; SKIN BURNING SENSATION; SKIN IRRITATION; STRABISMUS; SYNCOPE; TABLET; TACHYCARDIA; TINCTURE; URTICARIA; VASCULITIS; VOMITING; WHEEZING;

EID: 3242790887     PISSN: 00446394     EISSN: None     Source Type: Journal    
DOI: 10.1097/00012995-200310000-00001     Document Type: Review

References (50)

1. Weiner M, Bernstein IL. Adverse reactions to drug formulation agents: a handbook of excipients. New York: Marcel Dekker, Inc., 1989:133-58.
2. Mattar ME, Markello J, Yaffe SJ. Pharmaceutic factors affecting pediatric compliance. Pediatrics 1975; 55: 101-8.
3. Pawar S, Kumar A. Issues in the formulation of drugs for oral use in children. Pediatric Drugs 2002; 4: 371-9.
4. de Jong HJ. The safety of pharmaceutical excipients. Therapie 1999; 54: 11-14.
5. Smith JM, Dodd TRP. Adverse reactions to pharmaceutical excipients. Adverse Drug Reaction 1982; 1: 93-142.
6. Golightly LK, Smolinske SS, Bennett ML, Sutherland EW, Rumack BH. Pharmaceutical excipients, adverse effects associated with 'inactive' ingredients in drug products (part I). Medical Toxicology 1988; 3: 128-65.
7. Golightly LK, Smolinske SS, Bennett ML, Sutherland EW, Rumack BH. Pharmaceutical excipients, adverse effects associated with 'inactive' ingredients in drug products (part II). Medical Toxicology 1988; 3: 209-40.
8. Committee on Drugs. 'Inactive' ingredients in pharmaceutical products. American Academy of Pediatrics 1985; 76: 635-43.
9. Committee on Drugs. 'Inactive' ingredients in pharmaceutical products: update. American Academy of Pediatrics 1997; 99: 268-78.
10. Bigeard L. The role of medication and sugars in pediatric dental patients. Dental Clinics of North America 2000; 44: 443-56.
11. Kumar A, Weatherly MR, Beaman DC. Sweeteners, flavorings and dyes in antibiotic preparations. Pediatrics 1991; 87: 352-60.
12. Kumar A, Rawlings RD, Beaman DC. The mystery ingredients: sweeteners, flavorings, dyes, and preservatives in analgesic/antipyretic, antihistamine/decongestant, cough and cold, antidiarrheal, and liquid theophylline preparations. Pediatrics 1993; 91: 927-33.
13. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder SJ, Kauffman RE. Developmental pharmacology - drug disposition, action and therapy in infants and children. New England Journal of Medicine 2003; 349: 1157-67.
14. Hasley NA, Goldman L. Balancing risks and benefits: primum non nocere is too simplistic. Pediatrics 2001; 108: 466-7.
15. Gupta A, Waldhauser LK. Adverse drug reactions from birth to early childhood. Pediatric Clinics of North America 1997; 44: 79-92.
16. Martin G, Finberg L. Propylene glycol: a potentially toxic vehicle in liquid dosage form. Journal of Pediatrics 1970; 77: 877-8.
17. Weiss B, Williams JH, Margen S, et al. Behavioral responses to artificial food colors. Science 1980; 207: 1487-9.
18. Arulanantham K, Genel M. Central nervous system toxicity associated with ingestion of propylene glycol. Journal of Pediatrics 1978; 93: 515-16.
19. Bosso JA, Pearson RE. Sugar content of selected liquid medicinals. Diabetes 1973; 22: 776-84.
20. Feigal RJ, Jensen ME, Mensing CA. Dental caries potential of liquid medications. Pediatrics 1981;68:416-19.
21. Fotisch K, Fah J, Wuthrich B, Altmann F, Haustein D, Vieths S. IgE antibodies specific for carbohydrates in a patient allergic to gum arabic (Acacia senegal). Allergy 1998; 53: 1043-51.
22. Gordon HH. Episodic urticaria due to saccharin ingestion. Journal of of Allergy and Clinical Immunology 1975; 56: 78-9.
23. Lockey SD. Reactions to hidden agents in foods, beverages and drugs. Annals of Allergy 1971; 29: 461-6.
24. Lieb J, Kazienko DJ. Lactose filler as a cause of drug-induced diarrhea. New England Journal of Medicine 1978; 299: 314.
25. Miller R, White LW, Schwartz HJ. A case of episodic urticaria due to saccharin ingestion. Journal of Allergy and Clinical Immunology 1974; 53: 240-2.
26. Roberts IF, Roberts GJ. Relation between medicines sweetened with sucrose and dental disease. British Medical Journal 1979; 2: 14-16.
27. Settipane, GA. Adverse reactions of aspirin and related drugs. Archives of Internal Medicine 1981; 141: 328-32.
28. AMA Council on Scientific Affairs. Saccharin: review of safety issues. Journal of the American Medical Association 1985; 254: 2622-4.
29. Michaelsson G, Pettersson L, Juhlin L. Purpura caused by food and drug additives. Archives of Dermatology 1974; 109: 49-52.
30. Steinberg M, Borzelleca JF, Enters EK, et al. A new approach to the safety assessment of pharmaceutical excipients. Regulatory Toxicology and Pharmacology 1996; 24: 149-54.
31. US Food and Drug Administration. Aspartame: decision of the public board inquiry. Bethesda (MD): Food and Drug Administration, 1980. Docket No 75F-0355.
32. Schiffman SS, Buckley CE, Sampson HA, et al. Aspartame and susceptibility to headache. New England Journal of Medicine 1987;317:1181-5.
33. Inactive ingredient guide. Division of Drug Information Resources, Center for Drug Evaluation and Research Office of Management; Food and Drug Administration; Washington, DC: January 1996.
34. Newberne P, Smith RL, Doull J, et al. GRAS flavoring substances 19. Food Technology 2000; 54: 66-84.
35. Baldrick P. Pharmaceutical excipients development: the need for preclinical guidance. Regulatory Toxicology and Pharmacology 2000; 32: 210-18.
36. Fischetti F. Naural and artificial flavors. In: Furia TE, ed. CRC Handbook of Food Additives. Boca Raton, FL: CRC Press; 1980: 229-326.
37. Chafee FH, Settipane GA. Asthma caused by FD&C approved dyes. Journal of Allergy 1967, 40: 65-72.
38. Desmond RE, Trautlein JJ. Tartrazine (FD&C Yellow #5) anaphylaxis: a case report. Annals of Allergy 1981; 46: 81-2.
39. Haas S. Contamination of protejn-bound iodine by pink gelatin capsules colored with erythrosine. Annals of Internal Medicine 1970; 72: 549-52.
40. Hariparsad D, Wilson N, Dixon C, Silverman M: Oral tartrazine challenge in childhood asthma: effect on bronchial reactivity. Clinical Allergy 1984; 14: 81-5.
41. Jenkins P, Michelson R, Emerson PA. Adverse drug reaction to sunset-yellow in rifampicin/isomazid tablet. Lancet 1982; 2: 385.
42. Lockey SD. Hypersensitivity to tartrazine (FD&C yellow no.5) and other dyes and additives present in foods and pharmaceutical products. Annals of Allergy 1977; 38: 206-10.
43. Noonan JE, Meggos H. Synthetic food colors. In: Furia, TE. CRC Handbook of Food Additives. 2nd ed. Florida: CRC Press; 1980: 339-383.
44. Trautlein JJ, Mann WJ. Anaphylactic shock caused by yellow dye (FD&C no.5 and FD&C no.6) in an enema (case report). Annals of Allergy 1978; 41: 28-9.
45. Weber RW, Hoffman M, Raine DA, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. Journal of Allergy and Clinical Immunology 1979; 64: 32-7.
46. Barany E, Lindberg M, Loden M. Unexpected skin barrier influence from nonionic emulsifiers. International Journal of Pharmaceutics 2000; 195: 189-95.
47. Vie K, Pons-Guiraud A, Dupuy P, Maibach H. Tolerance profile of a sterile moisturizer and moisturizing cleanser in irritated and sensitive skin. American Journal of Contact Dermatitis 2000; 11: 161-4.
48. Sakaguchi M, Kaneda H, Inouye S. A case of anaphylaxis to gelatin included in erythropoietin products. Journal of Allergy and Clinical Immunology 1999; 103: 349-50.
49. Hurie MB, Saari TN, Davis JP. Impact of the joint statement by the American Academy of Pediatrics/US public health service on thimerosal in vaccines on hospital infant hepatitis B vaccination practices. Pediatrics 2001; 107: 755-8.
50. Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001; 107: 1147-54.